Premium
Exome sequencing allows for rapid gene identification in a Charcot‐Marie‐Tooth family
Author(s) -
Montenegro Gladys,
Powell Eric,
Huang Jia,
Speziani Fiorella,
Edwards Yvonne J.K.,
Beecham Gary,
Hulme William,
Siskind Carly,
Vance Jeffery,
Shy Michael,
Züchner Stephan
Publication year - 2011
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.22235
Subject(s) - exome sequencing , sanger sequencing , exome , genetics , nonsynonymous substitution , biology , genetic testing , mutation , genetic heterogeneity , dna sequencing , gene , exon , disease , phenotype , computational biology , bioinformatics , medicine , genome , pathology
Objective: Charcot‐Marie‐Tooth (CMT) disease comprises a large number of genetically distinct forms of inherited peripheral neuropathies. The relative uniform phenotypes in many patients with CMT make it difficult to decide which of the over 35 known CMT genes are affected in a given patient. Genetic testing decision trees are therefore broadly based on a small number of major subtypes (eg, CMT1, CMT2) and the observed mutation frequency for CMT genes. Since conventional genetic testing is expensive many rare genes are not being tested for at all. Methods: Whole‐exome sequencing has recently been introduced as a novel and alternative approach. This method is capable of resequencing a nearly complete set of coding exons in an individual. We performed whole‐exome sequencing in an undiagnosed family with CMT. Results: Within over 24,000 variants detected in 2 exomes of a CMT family, we identified a nonsynonymous GJB1 ( Cx32 ) mutation. This variant had been reported previously as pathogenic in X‐linked CMT families. Sanger sequencing confirmed complete cosegregation in the family. Affected individuals had a marked early involvement of the upper distal extremities and displayed a mild reduction of nerve conduction velocities. Interpretation: We have shown for the first time in a genetically highly heterogeneous dominant disease that exome sequencing is a valuable method for comprehensive medical diagnosis. Further improvements of exon capture design, next‐generation sequencing accuracy, and a constant price decline will soon lead to the adoption of genomic approaches in gene testing of Mendelian disease. Ann Neurol 2011;